Legend Biotech Posts $359.5M in Q3 Revenue
LEGN sits 46% above its 52-week low of $16.24.
Summary
Legend Biotech reported third-quarter revenue of $359.5M and third-quarter EPS of 13c. That follows the October 13 disclosure of preliminary Q3 CARVYKTI net trade sales of roughly $710M, up from $657M in the prior period, so the top line is now on the table in full. The number matters because CARVYKTI is the whole story here — the company's valuation rests on how fast that franchise scales, and revenue is the cleanest read on it. The wire headline carries no margin or guidance figures, so the read-through on spending and cash burn is still missing. Watch the full release and call for CARVYKTI growth cadence and any update to the 2026 outlook.
At the time of this announcement, LEGN was trading at $23.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $16.24 to $37.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.